Replies to post #23041 on ScripsAmerica Inc. (SCRCQ)

[Sandan]

The writer should do a little more DD on the rapimeds BS
China meeting,ect...
Why don't we ever hear of them trying to launch in otter
Markets..imo it's all BS

[coolerheadsprevail]

Just like with the "analyst report" from SeeThruEquity, non-CORE shareholders should understand what this penny stock newsletter article is and what it is not -- and take advantage and play this accordingly. I would suspect that most have fairly quickly recognized this as a pump based on NOTHING of substance, but rather based on stale forward-looking statements and a distorted spin on the low Q1'15 numbers... ...here are notable excerpts...

ScripsAmerica, Inc. (OTCMKTS:SCRC) highly efficient marketing and distribution platform

Highly efficient marketing platform??? You mean the marketing platform that dished out a horrid 65% selling expense rate for commissions? The one that resulted in SCRC experiencing record approved orders in Q4'14 (which translated to an annual run rate of almost $65M) but STILL losing money?

SCRC has been putting out a number of significant press releases in recent weeks including the one on June 3 that started it all; they announced that the Company has begun discussions with Forbes Investment Ltd. to market, supply, distribute and adapt its RapiMed(R) products throughout China.

This one is pretty funny. See how the author refers to a "recent" PR from June 3? If folks haven't figured it out by now, he is referring to an uber-stale PR from LAST YEAR when the hype was still about RapiMed "imminently" launching in mainland China, LOL...

ScripsAmerica is expected to generate net income of $400,000 on nearly $10 million of revenue, significant increases from revenue of $617,000 and a loss of $1.2 million for the same period in 2014. Growth at Main Avenue Pharmacy was driven by over $8.7 million of first quarter Approved Orders.

Ahhh, the continued spin of trying to compare the Q1'15 apple to the Q1'14 orange -- remember, folks, Main Ave did not even launch until mid-FEB'2014, so this is an intentionally deceptive comparison that BS Schneiderman has been pumping for a while now. It is essentially the textbook "Hey everyone, look at how well Q1'15 did compared to Q1'14! No no no, don't look at Q4'14, keep your eyes on Q1'14! Yes, that's right, just look at how awesome our Q1'15 numbers are compared to the Q1'14 period... ...And I'll be sure to NOT tell you that Main Ave didn't even exist until halfway thru Q1'14... ...and I also WON'T tell you that compared to the more recent and relevant Q4'14 period, our approved orders actually DECLINED over 60% in Q1'15... ...and I'll be sure to also NOT tell you that CVS/Caremark, the nation's 2nd largest pharmacy benefits manager terminated their agreement with us effective 3/13/15... ...so just keep your gaze firmly affixed to Q1'14 numbers, OK, everybody?"


And here is the best part: If you look at the website of the penny stock newsletter that wrote/distributed this article, you will find that they clearly tell you in their SEC disclosure:

"When we are compensated we alert opt-in MicroCapDaily subscribers via email and fully disclose any compensation in the disclaimer of the email including $ amount of compensation and 3rd party Payee. BELIEVE ABSOLUTELY NOTHING you see in Articles on MicroCapDaily.com."

Seriously. You just can't make this stuff up. The above is word for word verbatim from their own disclosures...